ptg-100
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02895100)
Timeline
Indications
Mechanism of action
- Integrin alpha-4/beta-7INHIBITOR
Integrin alpha-4/beta-7 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ptg-100
- ptg-100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04524221 | Phase 1 | Sep 30, 2020 | Protagonist Therapeutics, Stanford University |
| NCT02895100 | Phase 2 | Dec 1, 2016 | Protagonist Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Protagonist Therapeutics | For profit | 2 | 1 | 2 | 2016 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1